← Patent-cliff monitor small molecule VAFSEO VADADUSTAT
Loss of exclusivity March 2036 latest FDA-listed patent expiry
Drug detail Brand name VAFSEO Active ingredient VADADUSTAT Strength 450MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2024 Marketing status RX
Listed patents Patent Expires Type 11324734 March 2036 product 11844756 March 2036 use U-3876 9987262 November 2034 use U-3876 10149842 November 2034 substance, product 11065237 November 2034 substance, product 9701636 November 2034 substance, product 11857543 June 2034 use U-3876 12569474 June 2034 use U-3876 8323671 April 2028 use U-3876 7811595 March 2028 substance, product 8343952 August 2027 substance, product RE47437 June 2027 substance, product 8940773 June 2027 use U-3876 8598210 June 2027 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.